Evidence map›Paper›PMID 25392212›Full record

ArticleJournal of virology2015

Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity.

Gopi S Mohan, Ling Ye, Wenfang Li, Ana Monteiro, Xiaoqian Lin, Bishu Sapkota, Brian P Pollack, Richard W Compans, Chinglai Yang

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Ebola virus-like particles reprogram cellular metabolism.Journal of molecular medicine (Berlin, Germany) · 2023
    Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Ebolaviruses: New roles for old proteins.PLoS neglected tropical diseases · 2018
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Gopi S MohanDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Ling YeDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Wenfang LiDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Ana MonteiroDepartment of Pathology, Emory University, Atlanta, Georgia, USA.
Xiaoqian LinDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
Bishu SapkotaDepartment of Dermatology, Emory University, Atlanta, Georgia, USA.
Brian P PollackDepartment of Veterans' Affairs, Atlanta VA Medical Center, Decatur, Georgia, USA Department of Dermatology, Emory University, Atlanta, Georgia, USA.
Richard W CompansDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA rcompan@emory.edu chyang@emory.edu.
Chinglai YangDepartment of Microbiology and Immunology and Emory Vaccine Center, Emory University, Atlanta, Georgia, USA rcompan@emory.edu chyang@emory.edu.
Emory University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM008169 · NIGMS · EMORY UNIVERSITY · PI GROSS, ROBERT E · 1987 to 2021
$20.3M
A dual vaccine strategy against filovirus infectionR01AI093406 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 2011 to 2015
$5.1M
NIAID NIH HHS AI093406NIAID NIH HHS R01 AI093406NIGMS NIH HHS T32 GM008169
6 · The paper itself

Abstract

unlabelledThe Ebola virus (EBOV) surface glycoprotein (GP1,2) mediates host cell attachment and fusion and is the primary target for host neutralizing antibodies. Expression of GP1,2 at high levels disrupts normal cell physiology, and EBOV uses an RNA-editing mechanism to regulate expression of the GP gene. In this study, we demonstrate that high levels of GP1,2 expression impair production and release of EBOV virus-like particles (VLPs) as well as infectivity of GP1,2-pseudotyped viruses. We further show that this effect is mediated through two mechanisms. First, high levels of GP1,2 expression reduce synthesis of other proteins needed for virus assembly. Second, viruses containing high levels of GP1,2 are intrinsically less infectious, possibly due to impaired receptor binding or endosomal processing. Importantly, proteolysis can rescue the infectivity of high-GP1,2-containing viruses. Taken together, our findings indicate that GP1,2 expression levels have a profound effect on factors that contribute to virus fitness and that RNA editing may be an important mechanism employed by EBOV to regulate GP1,2 expression in order to optimize virus production and infectivity. IMPORTANCE: The Ebola virus (EBOV), as well as other members of the Filoviridae family, causes severe hemorrhagic fever that is highly lethal, with up to 90% mortality. The EBOV surface glycoprotein (GP1,2) plays important roles in virus infection and pathogenesis, and its expression is tightly regulated by an RNA-editing mechanism during virus replication. Our study demonstrates that the level of GP1,2 expression profoundly affects virus particle production and release and uncovers a new mechanism by which Ebola virus infectivity is regulated by the level of GP1,2 expression. These findings extend our understanding of EBOV infection and replication in adaptation of host environments, which will aid the development of countermeasures against EBOV infection.

Indexed as

Gene Expression Regulation, ViralVirus InternalizationVirus ReleaseVirus ReplicationCell LineEbolavirusHumansMembrane GlycoproteinsRNA EditingMembrane Glycoproteins

Identifiers

PMID25392212
PMCPMC4300637
OpenAlexW1996868126

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.